EXELIXIS : A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

16+Age Over 16

Thyroid<br/>CancersCancer LocationThyroid
Cancers

Systemic therapy | Head and neckHead and neck,Thyroid

Trial Overview Read MoreRead more

This phase III trial is trying to determine the effect of an oral chemotherapy (Cabozantinib) in patients with Differentiated Thyroid Cancer who have progressed on prior targeted treatment.
 

This trial is treating patients with differentiated thyroid cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy

Commercial Sponsor

Exelixis

Summary

Eligible patients will be randomised in a 2:1 ratio to receive either cabozantinib or placebo. All patients will receive oral tablets containing 60-mg or 20-mg cabozantinib or placebo equivalent once daily.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Endocrinology & Diabetes
Prahran
Faeeza Davids
f.davids@alfred.org.au
03 9076 5490

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next